13 July 2009 Topical application of ALA PDT for the treatment of moderate to severe acne vulgaris
Author Affiliations +
Proceedings Volume 7380, Photodynamic Therapy: Back to the Future; 73801Z (2009) https://doi.org/10.1117/12.822700
Event: 12th World Congress of the International Photodynamic Association, 2009, Seattle, Washington, United States
Abstract
Objectives: To evaluate the effectiveness of topical 5-aminolevulinic acid (ALA)- medicated photodynamic therapy (ALA PDT) for the treatment of moderate to severe acne vulgaris. Methods: Sixteen Chinese patients with moderate to severe facial acne were treated with 1-3 courses of ALA PDT. ALA cream (3%) was freshly prepared and applied to acne lesions for 3-4 h. The lesions were irradiated by a 635 nm diode laser at dose levels of 60 - 80 J/cm2 at 100 mW/cm2. Clinical assessments were conducted before and after treatment up to 3 months. Results: All patents showed response to ALA PDT. Complete clearance was seen in 10 patients (62.5%) and partial clearance in 6 patients (37.5%). One case showed recurrence after complete clearance at 2 months and another two showed recurrence after complete clearance at 3 months. However, the number of new lesions were significantly reduced. Adverse effects were minimal. Conclusions: The results of this preliminary clinical study is encouraging. ALA PDT is a simple, safe and useful therapeutic option for the treatment of moderate to severe acne. Further studies to evaluate the treatment with a larger number of patients and for a longer period of follow-up are needed.
© (2009) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Xiu-Li Wang, Hong-Wei Wang, Ling-Lin Zhang, Lina Su, Ming-Xia Guo, Zheng Huang, "Topical application of ALA PDT for the treatment of moderate to severe acne vulgaris", Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73801Z (13 July 2009); doi: 10.1117/12.822700; https://doi.org/10.1117/12.822700
PROCEEDINGS
6 PAGES


SHARE
Back to Top